ArticleBiochemistry and biophysics reports2025
The effect of platelet-rich plasma on ferroptosis of nucleus pulposus cells induced by Erastin.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Platelet-rich plasma may accelerate diabetic wound healing by modulating epithelial/endothelial-mesenchymal transition through inhibiting reactive oxygen species-mediated oxidative stress.Frontiers in bioengineering and biotechnology · 2025Article
- Efficacy of platelet-rich plasma injection with percutaneous endoscopic lumbar discectomy for lumbar disc herniation: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intervertebral disc degeneration (IVDD) has been linked to ferroptosis, a type of programmed cell death. The role of platelet-rich plasma (PRP) in mitigating ferroptosis in nucleus pulposus (NP) cells within IVDD remains unclear. Purpose: This study aims to verify the effectiveness of PRP in reducing ferroptosis in NP cells induced by Erastin. Methods: Primary NP cells were isolated from SD rats, and a ferroptosis model was established using Erastin. PRP was prepared and applied to assess its impact on ferroptosis-related markers, including reactive oxygen species (ROS), iron content, and glutathione peroxidase 4 (GPX4). The effects of PRP on the ultrastructure of NP cells were also observed using transmission electron microscopy (TEM). Results: PRP treatment significantly restored GPX4 levels (431.47 ± 4.70 ng/L vs. 69.70 ± 4.06 ng/L, P < 0.05), reduced ROS levels (45.06 ± 3.78 vs. 155.36 ± 3.56, P < 0.05), and decreased iron content (32.24 ± 096 μg/L vs. 59.25 ± 3.72 μg/L, P < 0.05) in ferroptotic NP cells compared to the sham group. Additionally, PRP significantly increased the expression levels of collagen Ⅱ (0.72 ± 0.02 vs. 0.33 ± 0.02, P < 0.05) and aggrecan (0.81 ± 0.01 vs. 0.31 ± 0.02, P < 0.05) compared to the sham group. TEM analysis also showed improvements in mitochondrial ultrastructure. These findings suggest that PRP can alleviate ferroptosis and promote cellular recovery. Conclusions: The study demonstrates the potential of PRP as a therapeutic intervention in IVDD by mitigating ferroptosis in NP cells, offering a new theoretical basis for PRP treatment in degenerative disc diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.